Jeffrey Settleman

发表

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

Ultan McDermott, Hannah Stubbs, T. Shioda, 2008, Cancer research.

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.

D. Haber, J. Settleman, K. Anderson, 2007, Cancer research.

Transitions between epithelial and mesenchymal states in development and disease.

Buzz Baum, J. Settleman, B. Baum, 2008, Seminars in cell & developmental biology.

Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes.

Somasekar Seshagiri, Li Li, Richard Bourgon, 2014, Cancer research.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Alona Muzikansky, Thomas J Lynch, Bruce E Johnson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor.

Ultan McDermott, U. McDermott, Sreenath V. Sharma, 2008, Methods in enzymology.

Detection of mutations in EGFR in circulating lung-cancer cells.

Mehmet Toner, Alona Muzikansky, Daniel Irimia, 2008, The New England journal of medicine.

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes

John L Cleveland, Masaaki Komatsu, Katsuhiko Kitamoto, 2008, Autophagy.

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Mari Mino-Kenudson, Keith T Flaherty, Erin M. Coffee, 2012, Cancer discovery.

SCFFBW 7 regulates cellular apoptosis by targeting MCL 1 for ubiquitylation and destruction

Yonghong Xiao, Andrew L. Kung, Steven P. Gygi, 2011 .

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Gayatry Mohapatra, D. Sgroi, D. Haber, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Epidermal growth factor receptor mutations in lung cancer

Daniel A. Haber, D. Haber, Sreenath V. Sharma, 2007, Nature Reviews Cancer.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Patricia L. Harris, Allan Wissner, Thomas J Lynch, 2005, Proceedings of the National Academy of Sciences of the United States of America.

GAP control: regulating the regulators of small GTPases.

J. Settleman, A. Bernards, Jeffrey Settleman, 2004, Trends in cell biology.

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

David N Louis, Ultan McDermott, Jeffrey W. Clark, 2010, EMBO molecular medicine.

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Anneleen Daemen, Deepak Sampath, Gerard Manning, 2015, Proceedings of the National Academy of Sciences.

A memory GAP

J. Settleman, Jeffrey Settleman, 2003, Trends in Neurosciences.

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Daniel A. Haber, D. Haber, J. Settleman, 2004, Science.

Rho-LIM Kinase Signaling Regulates Ecdysone-Induced Gene Expression and Morphogenesis during Drosophila Metamorphosis

J. Settleman, Guang-Chao Chen, Jeffrey Settleman, 2004, Current Biology.

Tension precedes commitment-even for a stem cell.

J. Settleman, Jeffrey Settleman, 2004, Molecular cell.

Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development.

Barry Fine, Le Zhang, Yoshihiko Yamada, 2002, Developmental cell.

A structure-guided approach to creating covalent FGFR inhibitors.

Scott B Ficarro, Nathanael S Gray, Matthew Meyerson, 2010, Chemistry & biology.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Jane Fridlyand, Antoni Ribas, Timothy R. Wilson, 2012, Nature.

Isoform-specific ras functions in development and cancer.

J. Settleman, M. P. Quinlan, Jeffrey Settleman, 2009, Future oncology.

Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis

David J Riese, J. Settleman, Jeffrey Settleman, 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

The complexity of targeting EGFR signalling in cancer: from expression to turnover.

Angelo Paradiso, Amalia Azzariti, A. Paradiso, 2006, Biochimica et biophysica acta.